The Seed Investor News Roundup

Biosynthesis: Unlocking the Medical Potential of Cannabis

View the infographic on how Biosynthesis could unlock the full medical potential of Cannabis, unlocking massive market potential.

Read the Investors Guide To Newly Emerging Marijuana Markets

LEARN MORE

P.E.I. sets legal age for pot at 19, to be sold in government-owned stores and online

Legislation is expected to come into effect July 1, 2018.

Aurora Cannabis Rebuts CanniMed's Call for Government Intervention to Block Takeover Bid

Saskatchewan Government Rejects CanniMed CEO's Plea. Aurora Intends to Establish Medical Cannabis Centre of Excellence in Saskatchewan

TerrAscend closes $52,500,000 private placement financing

TerrAscend Corp. (CSE: TER) announces that it has closed the previously announced non-brokered private placement whereby funds advised by JW Asset Management, LLC, Canopy Growth Corporation and Canopy Rivers Corporation acquired from TerrAscend, an aggregate of 47,727,273 units of the Company at a price per unit of $1.10 for aggregate gross proceeds of approximately $52,500,000.

MPX Bioceutical Receives Both Municipal and State Approval for GreenMart of Nevada NLV License Transfer

MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF) today announced that the Company, through its wholly-owned U.S. subsidiary, CGX Life Sciences Inc., has been granted both Municipal and State approval for the license transfer of GreenMart of Nevada NLV, LLC, an award winning licensed cultivation, production and wholesale business located in Las Vegas, Nevada.

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.

TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260

info@theseedinvestor.com

To keep receiving emails from us, please add us to your address book.